About Lab21
Lab21 is a company based in Cambridge (United Kingdom) founded in 2005 by Graham Mullis was acquired by Novacyt in May 2014. Lab21 has raised $837.8 thousand across 1 funding round from investors including Trinity Biotech and Novacyt. Lab21 has completed 1 acquisition, including Selah Technologies.
- Headquarter Cambridge, United Kingdom
- Founders Graham Mullis
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name The Lab21 Ltd
- Date of Incorporation 29 Dec, 2020
- Jurisdiction BUSHEY, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$837.8 K (USD)
in 1 rounds
-
Latest Funding Round
$837.8 K (USD), Seed
Oct 26, 2010
-
Investors
Trinity Biotech
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Lab21
Lab21 has successfully raised a total of $837.8K through 1 strategic funding round. The most recent funding activity was a Seed round of $837.8 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lab21
Lab21 has secured backing from 2 investors. Prominent investors backing the company include Trinity Biotech and Novacyt.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of In vitro diagnostic kits for clinical labs
|
Locked | Locked | Locked | |
|
Developer of cytology instruments and consumables for oncology and infectious disease
|
Locked | Locked | Locked |
Investor details for Lab21
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lab21
Lab21 has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Selah Technologies.
Investment portfolio details for Lab21
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nano-enabled advanced materials are manufactured using proprietary nanotechnology products.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Lab21
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lab21
Detailed financials for Lab21
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lab21 Comparisons
Peer comparison for Lab21
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lab21
Detailed competitors of Lab21
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lab21
Complete news archive for Lab21
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lab21
Lab21 was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Lab21 is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Lab21 is a funded company, having raised a total of $837.8K across 1 funding round to date.
Lab21 was founded in 2005 in Cambridge, United Kingdom, within the personalised medicine diagnostics sector. Molecular testing services for cancer and virology diagnosis, along with treatment optimisation, are offered to patients. Proprietary antibodies and antigens for infectious diseases such as syphilis, CMV, TB, and malaria are manufactured. These products are distributed globally to blood banking and diagnostic markets.
Lab21 has made 1 acquisition, including Selah Technologies.
Lab21 has 2 investors. Key investors include Trinity Biotech, and Novacyt.